Valuation: Titan Pharmaceuticals, Inc.

Market Cap 6.13M 5.5M 5.08M 4.61M 8.61M 582M 8.72M 60.93M 24.2M 305M 23.02M 22.53M 968M P/E 2023
-1.11x
P/E 2024 -0.62x
Enterprise Value 3.3M 2.96M 2.74M 2.48M 4.64M 314M 4.69M 32.8M 13.03M 164M 12.39M 12.13M 521M EV / Sales 2023
0.11x
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 184K 165K 152K 138K 258K 17.48M 262K 1.83M 726K 9.16M 691K 676K 29.05M -
Net income -5.57M -5M -4.62M -4.19M -7.82M -529M -7.92M -55.33M -21.97M -277M -20.9M -20.46M -879M -4.71M -4.22M -3.9M -3.54M -6.61M -447M -6.69M -46.76M -18.57M -234M -17.66M -17.29M -743M
Net Debt -6.2M -5.56M -5.13M -4.66M -8.7M -588M -8.81M -61.55M -24.44M -308M -23.25M -22.76M -978M -2.83M -2.54M -2.35M -2.13M -3.98M -269M -4.03M -28.13M -11.17M -141M -10.63M -10.4M -447M
Logo Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Employees
-
Sector
-